On March 18, 2026 BridgeBio Oncology Therapeutics, Inc. ("BBOT") (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, reported multiple presentations at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026 being held on April 17-22, 2026, in San Diego, California. The abstracts released today can be found on the AACR (Free AACR Whitepaper) website here.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details on the presentations are as follows:
Title: The RAS: PI3Kα breaker BBO-10203 inhibits PI3Kα/AKT activity in HER2+ models through non-canonical RAS signaling blockade
Session Category: Experimental and Molecular Therapeutics
Session Title: Targeted Protein Degradation and Non-cannonical Oncogenic Signaling
Session Type: Oral Presentation
Session Date/Time: Tuesday, April 21, 2:30 p.m. – 4:30 p.m. PT
Location: Upper Level Ballroom 6DE
Abstract Number: 6780
Presenter: James Stice, PhD, Director, BBOT
Title: BBO-11818: an orally bioavailable, highly potent and selective non-covalent pan-KRAS (ON) and (OFF) inhibitor with robust anti-tumor activity in KRAS-mutant preclinical models
Session Category: Experimental and Molecular Therapeutics
Session Title: Novel Antitumor Agents 3
Session Type: Poster Presentation
Session Date/Time: Wednesday, April 22, 9:00 a.m. – 12:00 p.m. PT
Location: Poster Section 13
Poster Board Number: 24
Poster Number: 7104
Presenter: Carlos Stahlhut, PhD, Associate Director, BBOT
About BBO-11818
BBO-11818 is a selective, orally bioavailable non-covalent inhibitor that targets KRAS in both the ON and OFF states, has high selectivity over HRAS and NRAS, and displays strong activity in KRAS-mutant preclinical models, including KRASG12D and KRASG12V. BBO-11818 potently suppresses MAPK signaling and inhibits cell proliferation in KRAS-mutant cell lines and mouse models. BBO-11818 is currently being evaluated in the Phase 1 KONQUER-101 trial in subjects with locally advanced unresectable or metastatic KRAS-mutant solid tumors.
About BBO-10203
BBO-10203 is a first-in-class small molecule which breaks the protein-protein interaction between RAS and PI3Kα and inhibits RAS-mediated activation of the PI3Kα pathway. It selectively disrupts oncogenic RAS-PI3Kα signaling while sparing insulin-mediated glucose uptake, potentially maintaining efficacy with reduced risk of hyperglycemia or hyperinsulinemia. BBO-10203 is currently being evaluated in the Phase 1 BREAKER-101 trial for patients with locally advanced or metastatic HER2+ breast cancer, HR+/HER2- breast cancer, KRAS-mutant colorectal cancer, and KRAS-mutant non-small cell lung cancer.
(Press release, BridgeBio Oncology Therapeutics, MAR 18, 2026, View Source [SID1234663727])